Generics Products found!

Innovative

Biosimilars

Medical devices

Nutraceuticals

Filters

Olmesartan medoxomil manufacturers

Filters

Filters

Filters , active

Country of origin : India

Clear all

None products found

olmesartan medoxomil

Tablets, film coated 20 mg, 40 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17459
This pharmaceutical company is a rapidly growing force in the global healthcare market, specializing in high-quality, affordable medications. They boast a diverse product portfolio encompassing prescription drugs, over-the-counter medications, and supplements, targeting key therapy areas like anti-Alzheimer's, asthma, diabetes, and cardiovascular health. The company holds WHO-GMP certifications and international approvals, underscoring their commitment to quality and regulatory compliance. Their manufacturing facilities are equipped with state-of-the-art technology, ensuring the production of safe and effective medicines. They distribute their products widely across multiple regions, including South East Asia and the Middle East, leveraging a robust network of distributors and consignees. Their mission is to provide accessible and affordable healthcare solutions worldwide, aiming to be a trusted partner for high-quality pharmaceuticals globally.

Manufacturer usually replies in 2 days

olmesartan medoxomil + amlodipine

Tablets 20 mg + 5 mg, 40 mg + 5 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20224

The company is a pharmaceutical manufacturer engaged in the manufacturing of a wide range of pharmaceutical products including tablets, injections, syrups, suspensions and capsules, producing these pharmaceutical products in accordance with established industry norms and supplying them to clients through commercial channels to meet healthcare requirements.

olmesartan medoxomil

Tablets 5 mg, 20 mg, 40 mg

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Registered in
United States
Available for
Licensing with supply, Distribution only
Manufacturer #18226
The company has a strong global presence, partnering with over 100 pharmaceutical companies and distributors across 28 countries, including regions such as North America, Europe, Latin America, Southeast Asia, CIS, Russia, the Middle East, and Africa. It operates 10 manufacturing facilities with approvals from major regulatory bodies, including the US FDA, UK MHRA, Korea KFDA, Ukraine GMP, and others, ensuring compliance with international standards. With a focus on research and development, manufacturing, and business development, the company leverages over 30 years of experience in oral solid dosage forms to expand rapidly into nutraceuticals and injectables, maintaining a robust and versatile product portfolio.

Manufacturer usually replies in 29 days

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription
Olmesartan Medoxomil is a synthetic imidazole derivative prodrug with an antihypertensive property. Olmesartan Medoxomil is a member of biphenyls. Upon hydrolysis, Olmesartan Medoxomil is converted to Olmesartan. Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs. Olmesartan is commonly used for the management of hypertension and Type 2 Diabetes associated nephropathy, heart failure, and post-myocardial infarction particularly in patients who are unable to tolerate ACE inhibitors. Olmesartan is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents. Manufacturers of Olmesartan Medoxomil market these drugs under the Brand name of Benicar, Olmetec. This drug comes only as a tablet which is taken by mouth. Olmesartan Medoxomil is available in 5 mg, 20 mg, 40 mg dosage strengths. 5 mg tablets are yellow, round, film coated tablets identified by a debossed code “C12” on one side and manufacturer name on the other. 20 mg tablets are white, round, film coated tablets identified by a debossed code “C14” on one side and manufacturer name on the other. 40 mg tablets are white, oval shaped, film coated tablets identified by a debossed code “C15” on one side and manufacturer name on the other. For Hypertension, the usual recommended starting dose of Olmesartan Medoxomil is 20 mg once daily and for patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose may be increased to 40 mg. Dose above 40 mg do not appear to have grater effect. Twice-daily dosing offers no advantage over the same. The approved storage conditions for Olmesartan Medoxomil is at 20° C - 25° C (68° F - 77° F). Wholesale Price of Olmesartan Medoxomil The wholesale price for 30 units of 5 mg Olmesartan Medoxomil oral tablet is approximately $ 57.07 with per unit cost comes at $ 1.90. The lowest available wholesale price for the quantity of 1000 Olmesartan Medoxomil tablets is $ 1595.20 with per unit costs as low as $ 1.60 The per unit cost of 20 mg Olmesartan Medoxomil oral tablet is approximately $ 2.20, which is available for a price of around $ 66.00 for 30 tablets whereas for a set of 90 tablets it costs approximately $ 179.01, with per unit cost $ 1.99 The 40 mg tablets are available at a price range of $ 78.63 - $ 88.04 for a set of 30 tablets with per unit ranges between $ 2.62 - $ 2.93 Olmesartan Medoxomil - Mechanism of Action Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects. As the principal pressor agent of the renin-angiotensin system, Angiotensin II causes vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Overall, Olmesartan’s physiologic effect lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity and increased excretion of sodium. Finding Olmesartan Medoxomil Manufacturers and Suppliers Finding a trustful partner in our business is one of the biggest challenges and to overcome that challenge and to make one’s work / life easy in finding the trusted manufacturer and supplier of Olmesartan Medoxomil one can visit the Pipelinepharma website which helps you in finding the trusted manufacturers and suppliers of Olmesartan Medoxomil. Pipelinepharma, which is a business-to-business (B2B) licensing marketplace for pharmaceutical products that quickly connects owner with the customers for the business development. You can filter the product names in user friendly and unified search engine by its country, category, therapeutic area, forms, dossier and its status, regulatory filings, approvals, and more.

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.